Abstract
Autologous cells replacement therapy by liver to pancreas transdifferentiation (TD) allows diabetic patients to be also the donors of their own therapeutic tissue. Aim: To analyze whether the efficiency of the process is affected by liver donors' heterogeneity with regard to age, gender and the metabolic state. Materials & methods: TD of liver cells derived from nondiabetic and diabetic donors at different ages was characterized at molecular and cellular levels, in vitro. Results: Neither liver cells proliferation nor the propagated cells TD efficiency directly correlate with the age (3-60 years), gender or the metabolic state of the donors. Conclusion: Human liver cells derived from a wide array of ages and metabolic states can be used for autologous cells therapies for diabetics.
| Original language | English |
|---|---|
| Pages (from-to) | 19-31 |
| Number of pages | 13 |
| Journal | Regenerative Medicine |
| Volume | 16 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2 Feb 2021 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- adult cell reprogramming
- cell replacement therapy
- diabetes
- liver
- pancreatic transcription factors
- transdifferentiation
Fingerprint
Dive into the research topics of 'The effect of liver donors' age, gender and metabolic state on pancreatic lineage activation'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver